Active Infection & Immunity NIHR-supported project Cancer

A Phase I Study to assess the safety and immunogenicity of MVA based vaccine for Hantavirus (MVA-Hanta)

Funder NIHR (part of DHSC)
Recipient organisation NIHR Southampton Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Jan 2025 — Mar 2027

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Alasdair Munro (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

Advancement of a cost-effective MVA-based Hantavirus vaccine (HantaVacc).
A Phase I Study to assess the safety and immunogenicity of a MVA based vaccine for Crimean-Congo Haemorrhagic Fever (MVA-CCHF)
Multi-valent Hantvirus-Vaccine (MVA SEO-HTN: Vacc) and a ferret model of disease
A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mHAg) HA-1 using a DNA and MVA 'prime/boost' regimen. (HA-1)
A phase 1 dose escalation open label trial to assess safety and immunogenicity of candidate ChAdOx1- and MVA-vectored conserved mosaic HIV-1 vaccines, given sequentially to healthy HIV-1/2-negative adult volunteers in Oxford, UK

Original classification

Microbiology, Immunology and Infection (MII)

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.